Literature DB >> 6848253

Measurement of nifedipine in plasma by gas--liquid chromatography and electron-capture detection.

S R Hamann, R G McAllister.   

Abstract

In this method for measuring nifedipine, a calcium-channel inhibitor now widely used in the treatment of cardiovascular disease, the drug is extracted from plasma under basic conditions into toluene, and an aliquot of the extract is injected directly into a gas chromatograph equipped with an OV-101 column and an electron-capture detector. The standard curve is linear between 1 and 100 micrograms/L; the assay measures not only nifedipine, but also a major metabolic product (found only after oral administration of the parent drug) and photodegradation products. The procedure is rapid and adequately sensitive for routine use in clinical monitoring of nifedipine in plasma.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6848253

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  10 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  Complexation of nifedipine with substituted phenolic ligands.

Authors:  K M Boje; M Sak; H L Fung
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

3.  Non-bioequivalence of sublingual nifedipine.

Authors:  N Rietbrock; M Kausch; M Engelhardt; B G Woodcock
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

4.  Comparison of effects of nifedipine, propantheline bromide, and the combination on esophageal motor function in normal volunteers.

Authors:  M Hongo; M Traube; R W McCallum
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

5.  Effect of nifedipine on gastric emptying in normal subjects.

Authors:  M Traube; R C Lange; R G McAllister; R W McCallum
Journal:  Dig Dis Sci       Date:  1985-08       Impact factor: 3.199

6.  Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.

Authors:  L A Bauer; K Murray; J R Horn; K Opheim; J Olsen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

8.  The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects.

Authors:  F Pasanisi; P A Meredith; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Authors:  C H Kleinbloesem; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

10.  Effect of nifedipine on mouth-to-cecum transit of liquid meal in normal subjects.

Authors:  G Chiarioni; C Scattolini; F Bonfante; M T Brentegani; I Vantini
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.